Acute Myeloid Leukemia as a Trigger for Hemolytic–Uremic Syndrome
Acute myeloid leukemia (AML) has not been identified as a cause of secondary hemolytic-uremic syndrome (HUS). This case report describes a woman who developed severe HUS at the time of AML diagnosis and responded favorably to initial treatment with eculizumab, which stabilized her condition and allowed for treatment of the AML. After one year, with stable renal function and genetic studies reported as normal, eculizumab was successfully discontinued. The prompt use of eculizumab was critical to the patient's survival and improvement in renal function, highlighting the efficacy of early eculizumab treatment in secondary HUS.
Authors
- Lluís Guirado (ORCID: https://orcid.org/0000-0001-5119-3912)
- Roser Torrá (ORCID: https://orcid.org/0000-0001-8714-2332)
- Montserrat M. Díaz Encarnación (ORCID: https://orcid.org/0000-0001-5172-3370)
- A. Guasch (ORCID: https://orcid.org/0000-0002-9322-7479)
- Xoana Barros Freiría (ORCID: https://orcid.org/0000-0001-9690-9769)
- Guadalupe Oñate (ORCID: https://orcid.org/0000-0003-2180-2371)
- Jonas El Bachouti
- Yolanda Arce (ORCID: https://orcid.org/0009-0004-2867-6050)
- Helena Marco (ORCID: https://orcid.org/0000-0003-3454-5837)
Institutions
- Hospital de Sant Pau (ES)
- Puigvert Foundation (ES)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2024-10-28
- DOI
- https://doi.org/10.3390/jcm13216468
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00